DNA 합성 시장, 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global DNA Synthesis Market garnered USD 4 billion in 2023 and is projected to grow at a CAGR of 18.9% from 2024 to 2032. This growth is driven by advancements in synthetic biology and gene editing technologies, such as CRISPR, and the increasing adoption of precision medicine. The focus on synthetic biology research is supported by substantial R&D investments and an expanding emphasis on DNA studies. Such funding supports technological advancements and amplifies synthetic biology's potential in the genome sector, driving market growth.

DNA synthesis involves the artificial creation of DNA molecules by chemically synthesizing nucleotide sequences in a lab. These sequences are used in genetic engineering, research, and biotechnology.

The market is segmented by service into oligonucleotide synthesis and gene synthesis. In 2023, oligonucleotide synthesis led the market with a 58% share, driven by its role in molecular diagnostics, genetic testing, synthetic biology, and gene editing. Technological advancements, such as automated synthesizers and high-throughput platforms, further boost the market by enhancing the scalability and efficiency of oligonucleotide synthesis.

The market is also segmented by method into chip-based synthesis, PCR-based enzyme synthesis, and solid-phase synthesis. Solid-phase synthesis held a significant market share in 2023 and is projected to reach USD 9 billion by 2032. Its dominance is due to its efficiency and adaptability in constructing DNA sequences on solid supports, allowing for step-by-step nucleotide addition. The method's scalability and cost-effectiveness make it suitable for both research and industrial applications.

By application, the DNA synthesis market includes research and development, diagnostics, and therapeutics. The research and development segment led the market in 2023 and is projected to grow at a CAGR of 19.3% during the analysis period. This segment's significant market share is due to its role in advancing biotechnology and pharmaceutical research. The rising demand for custom DNA sequences in drug discovery, experimental studies, and genetic engineering propels DNA synthesis growth.

The market is segmented by end use into biopharmaceutical companies, academic & research institutes, and contract research organizations. The biopharmaceutical companies segment is projected to grow at a CAGR of 18.4% from 2024 to 2032. This growth is driven by the demand for personalized medicine, where DNA synthesis is crucial in creating treatments tailored to individual genetic profiles. Biopharmaceutical firms are investing in DNA synthesis technologies to expedite drug discovery and development, leading to novel therapies.

In 2023, North America led the global DNA synthesis market with a 36.5% share and is projected to grow at a CAGR of 18.4% during the analysis period. The region's dominance is supported by a strong R&D infrastructure and a concentration of key players and leading research institutions focused on synthetic biology and gene editing. Collaborations highlight the region's leadership in advancing DNA synthesis technologies for critical healthcare solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of diseases globally
    • 3.2.1.2 Rapid technology advancements in the field of synthetic biology
    • 3.2.1.3 Rising investments towards research and development (R and D) activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent government regulations and guidelines
    • 3.2.2.2 High cost, potential biosafety, biosecurity and ethical issues
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
  • 4.1.1 Thermo fisher scientific Inc.
  • 4.1.2 Eurofins scientific
  • 4.1.3 GenScript biotech corporation
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Service, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Oligonucleotide synthesis
  • 5.2.1 Standard oligonucleotide synthesis
  • 5.2.2 Custom oligonucleotide synthesis
• 5.3 Gene synthesis
  • 5.3.1 Custom gene synthesis
  • 5.3.2 Gene library synthesis

Chapter 6 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Solid-phase synthesis
• 6.3 PCR-based enzyme synthesis
• 6.4 Chip-based synthesis

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Research and development
• 7.3 Diagnostics
• 7.4 Therapeutics

Chapter 8 Market Estimates and Forecast, By End use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Biopharmaceutical companies
• 8.3 Academic and research institutes
• 8.4 Contract research organizations

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 BIOMATIK
• 10.2 Bioneer Corporation
• 10.3 Eton Bioscience, Inc.
• 10.4 Eurofins Scientific
• 10.5 GenScript Biotech Corporation
• 10.6 IBA Lifesciences GmbH
• 10.7 Integrated DNA Technologies, Inc.
• 10.8 Kaneka Eurogentec S.A.
• 10.9 LGC Biosearch Technologies
• 10.10 OriGene Technologies, Inc.
• 10.11 ProMab Biotechnologies, Inc.
• 10.12 ProteoGenix
• 10.13 Quintara Biosciences
• 10.14 Synbio Technologies
• 10.15 Thermo Fisher Scientific Inc.
• 10.16 Twist Bioscience Corporation